Citadel Advisors
TIL icon

Citadel Advisors’s Instil Bio TIL Stock Holding History

Citadel Advisors’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Sell
30,639
-7,923
-21% -$63.9K ﹤0.01% 11681
2026
Q1 		$318K Sell
38,562
-8,773
-19% -$71.2K ﹤0.01% 10347
2025
Q4 		$521K Buy
+47,335
New +$700K ﹤0.01% 8938
2024
Q2 		– Sell
-15,438
Closed -$167K – 15402
2024
Q1 		$167K Sell
15,438
-12,860
-45% -$141K ﹤0.01% 10606
2023
Q4 		$216K Buy
28,298
+25,966
+1,113% +$188K ﹤0.01% 9801
2023
Q3 		$20K Sell
2,332
-7,957
-77% -$80.2K ﹤0.01% 12629
2023
Q2 		$113K Buy
10,289
+3,427
+50% +$41.9K ﹤0.01% 10735
2023
Q1 		$90.7K Sell
6,862
-16,838
-71% -$249K ﹤0.01% 11404
2022
Q4 		$299K Buy
23,700
+9,351
+65% +$462K ﹤0.01% 9332
2022
Q3 		$1.39M Sell
14,349
-3,158
-18% -$361K ﹤0.01% 6310
2022
Q2 		$1.62M Buy
17,507
+6,455
+58% +$914K ﹤0.01% 5996
2022
Q1 		$2.38M Buy
+11,052
New +$2.58M ﹤0.01% 5710
2021
Q3 		– Sell
-2,799
Closed -$1.08M – 14651
2021
Q2 		$1.08M Sell
2,799
-64
-2% -$23.7K ﹤0.01% 8174
2021
Q1 		$1.44M Buy
+2,863
New +$1.47M ﹤0.01% 7214

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $14.6M AUM 63.08% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Citadel Advisors's TIL Position: Q2 2026 in Review

Citadel Advisors reduced its Instil Bio (TIL) stake by 21% in Q2 2026, selling an estimated $63.9K and leaving 30,639 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #11681.

Citadel Advisors first reported a position in TIL in Q1 2021 and has held it in 14 quarters since. The position peaked at $2.38M in Q1 2022. 26 funds tracked by Wall St. Rank hold TIL as of Q2 2026.

  • Citadel Advisors held 30,639 shares of Instil Bio worth $236K as of Q2 2026.
  • Citadel Advisors sold 7,923 Instil Bio shares in Q2 2026, an estimated $63.9K.
  • Instil Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11681 holding.
  • Citadel Advisors first reported a position in Instil Bio in Q1 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Instil Bio position peaked at $2.38M in Q1 2022.
  • 26 funds tracked by Wall St. Rank held Instil Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.